Assessing the prognostic value of <i>KRAS</i> mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis.

However, as noted in another study ( 38 ), there was a tendency toward improved survival among KRAS G12C patients with stage II disease and T2/T3 tumors, although these differences did not reach statistical significance.

also in 111,027 other papers